HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results for the period ended March 31, 2026. The call will also provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is central to these initiatives. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform is designed for portable devices that can be used wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
The limited commercial launch for arrhythmia assessment represents a critical step in bringing this technology to market. Extended-wear patch development aims to provide longer-term monitoring capabilities, while heart attack detection programs seek to improve early identification of myocardial infarctions. The company's AI programs are expected to enhance diagnostic accuracy and predictive analytics, potentially transforming cardiac care management.
HeartBeam holds over 20 issued patents related to its technology enablement, underscoring its commitment to innovation in cardiac care. The company's platform technology is designed to deliver actionable heart intelligence, redefining the future of cardiac health management by allowing patients to receive care outside traditional medical facilities.
The upcoming call will be of interest to investors and healthcare professionals tracking advancements in remote cardiac monitoring and digital health. The implications of HeartBeam's technology could reduce the burden on healthcare systems by enabling earlier detection and intervention for cardiac conditions, potentially improving patient outcomes and lowering costs. For more details, the full press release is available at https://ibn.fm/yN939, and the latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
This announcement is based on a press release issued by HeartBeam and distributed by NEWMEDIAWIRE. The company's forward-looking statements are subject to risks and uncertainties as detailed in its filings with the SEC. The information provided in this article is for informational purposes only and should not be considered investment advice.
